GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) reported the engagement of Volker Knappertz, M.D. as its Chief Medical Officer. Reporting to company’s CEO Justin Gover, the new CMO will be based in the firm’s U.S. headquarters in California. In addition, the company reported that Professor Ben Whalley will be the new Head of Discovery Research, and he will be based in the U.K.
The CEO of GW Pharmaceutical reported that he is thrilled to welcome Knappertz and Whalley to company in these major R&D roles. Knappertz has a remarkable record of new drug development and getting regulatory approvals which, with his extensive experience in neurology, makes him suited to lead company’s regulatory and clinical activities pertaining to Epidiolex® and their product pipeline. Additionally, Whalley’s leading position in the segment of CBD science, especially pertaining to epilepsy, will be a major asset to company in the pursuit of their pipeline discovery programs.
Dr. Knappertz has clinical trial experience of over 25 years and pharmaceutical drug development experience of more than 17 years, holding leadership roles with responsibilities for managing global clinical study and medical affairs programs.
Recently, as the VP of clinical advancement for multiple sclerosis, oncology and biosimilar offerings at Teva Pharmaceuticals, Dr. Knappertz managed multiple regulatory filings and approvals in the United States, Europe, Japan and Canada. Prior to his role with Teva, Dr. Knappertz served in medical and clinical roles in CNS, biologics and CV at AstraZeneca and Bayer Pharmaceuticals.
Dr. Knappertz is a U.S. Board approved neurologist who obtained his residency training at Yale University, where he worked as chief resident and was trained at Wake Forest University. On his new role, Dr. Knappertz reported that he is extremely thrilled about the prospect to continue the work of offering regulatory approved CBD-based pharmaceutical drugs to patients with unmet medical needs.
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies